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Introduction
Hepatitis C virus (HCV) infection is considered a systemic disease, 1 and among extrahepatic manifestations, insulin resistance (IR) and diabetes are reported to be associated with high frequency to the infection. Chronic HCV infection is currently a major health problem on a global scale due to its high epidemiologic burden, widespread distribution, and severe hepatic and extrahepatic outcomes.
Both experimental and clinical studies 2 have demonstrated that HCV induces IR. In HCV-infected patients, the reported prevalence of IR ranges from 30% to 70%, regardless of severity of the hepatic disease, and is genotype-specific. 3, 4 In fact, patients with HCV genotype 3 infection showed a lower rate of IR than that observed for genotypes 1 and 4. 4 Moreover, a close correlation between the viral load and IR was observed in genotype 1 infection, indicating a possible direct link between the two conditions. 4 IR has a significant role in the development of type 2 diabetes, hepatic steatosis, and liver fibrosis.
2,3
The direct-acting antivirals (DAAs) have become the new gold standard of HCV treatment. 5 DAAs are safe and highly effective and achieve a sustained virologic response (SVR) in 90-98% of cases. 5 Given the postulate of direct involvement of HCV in the development of IR, we hypothesized that viral eradication by DAA treatments could improve or reverse IR. To test this hypothesis, we performed a prospective case-control study to evaluate the changes in IR in HCV-genotype-1 patients treated with DAAs who achieved SVR.
Methods
Study design and participants. Enrolled in this casecontrol study were consecutive HCV-genotype-1 infected patients with advanced liver fibrosis evaluated for DAA treatments. Excluded were patients co-infected with hepatitis B virus or human immunodeficiency virus (HIV) or with a history of alcohol abuse and diabetes mellitus or taking medications such as biguanides and thiazolidinediones.
Assessments. Patients were assessed for body mass index (BMI) and waist circumference, liver function tests, full blood count, serum fasting blood glucose, serum cholesterol and triglycerides, and liver ultrasound. Transient elastography by Fibroscan (Echosens, Paris, France) was used to evaluate liver fibrosis. The Italian access policy to DAA treatments at that time was restricted to patients with advanced liver disease with a value of fibroscan of Kpascal equal or greater than 10 (F3-F4).
Hepatitis C virus RNA levels were evaluated by real-time polymerase chain reaction (PCR) and HCV genotype by Innolipa assay.
Samples of plasma and serum taken before starting treatment, at the end of treatment, and 3 months after stopping treatment were stored at À80°C to be tested for blood insulin and glucose in one laboratory run. Control group was evaluated at time 0 and after 3 months.
Serum insulin was assessed by the immunoassay for human insulin (Insulin Cobas, Roche Diagnostics, Indianapolis, IN, USA). HOMA was used to evaluate IR and β-cell function by the following formulas: HOMA-IR = ([glycemia (mg/dL) × insulinemia (μU/mL)]/405); HOMA-B% = (360 × fasting insulin μU/mL)/(fasting glucose mg/dL À 62); and HOMA-S-% = 1/(log(fasting insulin μU/mL) + log(fasting glucose mg/dL). The cut-off level for the assessment of HOMA-IR was evaluated in 130 healthy Caucasian subjects from the same geographical area and was settled at 2.60 (75th percentile of HOMA-IR). 6, 7 Statistical analysis. Data are expressed as mean ± standard deviation. Significant differences between pre-treatment and posttreatment were evaluated by paired t-test for quantitative values and Chi-square test to identify significant differences in the prevalence. Spearman correlation was used to individuate factors associated with HOMA. Linear regression was used to individuate independent factors associated with HOMA-IR. Data were analyzed by SPSS 17.5, and a value of P < 0.05 was assumed as significant.
Results
Participants. Sixty-eight HCV-genotype-1 consecutive patients treated with all-oral DAAs and 65 HCV-genotype-1 patients undergoing evaluation and waiting for treatment used as control group were enrolled in the study. The characteristics of the patients are shown in Table 1 . At baseline, IR was showed in 52.3% and 53.8% of treated and control patients, respectively.
Treatments. The DAAs used for treatment were as follows: Simeprevir + sofosbuvir (±ribavirin) 43%; Ombitasvir/ paritaprevir/ritonavir + dasabuvir (±ribavirin) 45%; and Ledipasvir/sofosbuvi (±ribavirin) 12%. At the end of treatment, 100% of patients cleared HCV-RNA, and after 3 months follow up, SVR was observed in 65 (95.6%) patients.
Pre-direct-acting and post-direct-acting antivirals treatment changes in liver fibrosis and steatosis. The mean transient elastography value before treatment was Kpa 21.13 ± 11.16, at the end-treatment was 20.84 ± 9.60, and 3 months ALT, alanine aminotransferase; BMI, body mass index; DAA, direct-acting antiviral; HCV, hepatitis C virus; SVR, sustained virologic response.
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after the end of treatment, there was a significant reduction in this value (Table 1 ; P < 0.001) in 64 cases out of 65 SVR patients. In control group, there was no significant variation in the mean value of liver stiffness between baseline and after 3 months (Table 1) . There was no change in the levels of steatosis evaluated by ultrasound.
Pre-direct-acting and post-direct-acting antivirals treatment changes in insulin resistance, serum glucose, and serum insulin. During the study period, no patient changed his lifestyle or increased physical activity or changed the diet or assumed new medicines. The data on changes in HOMA-IR of the treated patients who achieved SVR and of the control patients, as well as serum glucose and serum insulin, are shown in Table 1 .
Comparing the values of end treatment with those of the baseline, a significant decrease in serum fasting glucose and insulin levels was observed; similarly, a significant reduction of mean HOMA-IR value was observed (Table 1 ; P < 0.001). Three months after treatment withdrawal, SVR patients maintained improvements in fasting glucose, serum insulin levels, and HOMA-IR observed at the end of the treatment (Table 1 ). There was no significant changes in IR, serum fasting glucose, and insulin levels in the control group (Table 1) . Interestingly, of the three patients with relapses, one had IR at the baseline, and at the end of treatment, all the three patients had a reduction in HOMA-IR values, but after relapse returning HOMA-IR values similar to baseline. The pre-treatment and posttreatment prevalence of IR in the 65 HCV patients who reached SVR is shown in Table 1 . Overall, 49 patients (75.4%) after SVR showed significant improvement in HOMA levels. A data analysis of 34 (52.3%) patients with pre-treatment IR showed that after SVR, 14 (41.2%) had normal IR values, 12 (35.2%) had a significant reduction in IR values, and only eight (23.5%) had no change in values. Thus, among these patients after viral eradication with DAA treatments, 76.5% of cases showed a positive impact on IR.
The quantitative insulin sensitivity check index and β-cell function are reported in Table 1 . A significant increase in HOMA-S and a significant reduction in HOMA-B were observed after HCV clearance.
At baseline, correlation analysis found that HOMA-IR was significantly associated with HCV RNA levels (coefficient correlation: 0.293, P = 0.018) while a trend was observed for BMI (P = 0.063) and Kilopascal (P = 0.073).
Linear regression analysis showed that HOMA-IR was independently associated only with HCV RNA (coefficient B: 0.0706, SE: 0.0304; P = 0.024; 95% confidence interval 0.097-1.314).
At 3 months of follow up, the persistence of IR was associated with the highest values of liver fibrosis (correlation: r = 0.26, P < 0.040) with average Kilopascal values for IR and non-IR of 17.91 ± 11.20 and 12.87 ± 7.51, respectively (P = 0.040; 95% confidence interval 0.238-9.84).
Discussion
Data from this study obtained in patients with advanced liver disease and without diabetes demonstrate that regardless of the degree of liver fibrosis and BMI, the clearance of HCV by DAA treatments induces an improvement or regression of the homeostasis of HCV-associated impaired glucose metabolism. In particular, a reduction in serum glucose and insulin levels, reduction of IR levels, and an improvement in insulin sensitivity have been observed; in addition, a reduction of β-cells distress was observed. Data also show that after HCV clearance, persistence of IR was mainly observed in patients with the highest levels of liver fibrosis indicating that such patients remain associated with some degree of the pathological condition.
Insulin resistance is a feature of chronic HCV infection reported in up to 70% of cases. 2 Experimental and clinical evidences 8, 9 demonstrated that HCV core protein plays a pathogenic role in the development of IR. Epidemiological studies show that the prevalence of IR and type 2 diabetes in HCV-infected patients is significantly higher than that observed in hepatitis B virus infection and in the general population. 2 It has been reported that the risk of developing type 2 diabetes mellitus is 11 times higher in patients with HCV infection 10 and that IR is the link between HCV infection and diabetes. In HCV patients, the presence of IR is associated with the development of hepatic steatosis, and both accelerate the progression of liver fibrosis.
11,12 IR is a condition associated with HCV genotypes especially in genotypes 1 and 4 4 in which there is a direct correlation between viremia and IR levels and the development of type 2 diabetes. 4, [13] [14] [15] The earlier data seem to indicate a direct role of HCV in the development of IR, and evidence shows that the appearance of IR in patients with chronic HCV hepatitis can be attributed to the virus by itself rather than advanced hepatic fibrosis. 4, 16, 17 Data from our study conducted in DAAs-treated advanced HCV liver disease patients who achieved SVR, regardless of changes in the degree of liver fibrosis and of BMI, showed an improvement or disappearance of IR in 76.5% of cases associated with an increase in insulin sensitivity and reduced stress of βeta-cell function. Such modifications were independently associated with HCV RNA levels and its disappearance. In addition, a significant reduction of pre-treatment and post-treatment fasting serum glucose and insulin levels has been observed. The data support the pathogenic role of HCV-genotype 1 in the development of IR. Our findings are in agreement with previous data that showed that interferon (IFN)-based treatment improves IR and blood glucose levels in patients who clear HCV. 9, [17] [18] [19] However, these data obtained on IFN-based treatments had an important confounding factor, that is, weight loss that was frequently associated with IFN treatment. 20 It has been demonstrated that weight loss causes a significant improvement in insulin sensitivity. 21 The data from the present study provide evidence of an improvement in IR after clearance of HCV by IFN-free all-oral DAA regimens in which weight loss does not occur as an adverse event of treatment. In fact, the BMI of our patients evaluated before and after treatment remained unchanged underling that the changes in IR were independent by BMI further supporting the role of HCV-genotype 1 in the development of IR. On the basis of these data, it is possible to hypothesize that HCV clearance by DAAs improving IR and reducing stress on βeta-cell function prevents or delay the development of type 2 diabetes mellitus and/or metabolic syndrome in chronic HCV-infected patients. In support of this hypothesis are the data from previous studies conducted on HCV patients after SVR by IFN-therapeutic regimens, which showed a twofold to threefold lower incidence of type 2 diabetes compared with those who did not achieve SVR. 20, 22, 23 Our study demonstrated that HCV patients reaching SVR have a better glycemic control; thus, it is possible to hypothesize that clearance of HCV in diabetic patients could improve the glucose homeostasis control. To corroborate this hypothesis, recently, it has been reported that a significant amelioration of glycemic control in diabetic HCV patients, who reached an SVR by DAAs despite a significant weight increase. 24 Furthermore, IR in HCV patients is strictly correlated with metabolic syndrome, as well as reduced levels of adiponectinemia 2, 25 and it is a determinant for increased vessel wall stiffness 26 and oxidative stress 27 ; thus, clearance of HCV could improve IR-related cardiovascular events. It has been reported that HCV patients who cleared the virus with IFN-based regimens had a reduced incidence and mortality rate for cardiovascular and for non-liver-related mortality in HCV patients. 28, 29 In conclusion, the overall data of this study show that the HCV clearance by DAA treatments reverses or improves IR and reduces stress on β-cell function by emphasizing the role of HCV in the development of IR and that this result can prevent IR-related pathological conditions such as worsening liver fibrosis, development of type 2 diabetes, metabolic syndrome, and cardiovascular disorders. However, considering that patients with very advanced hepatic fibrosis after HCV clearance have lower rate of IR improvement, antiviral treatment should be made in earlier phases of liver disease to obtain the best therapeutic result on IR and IR-related clinical manifestations and complications.
